Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty
The bimatoprost implant demonstrated statistical and clinical noninferiority to SLT in IOP reduction from baseline at weeks 4, 12, and 24. In subgroup analysis, patients with flexible implant readministration met the same criteria. Both the implant and SLT demonstrated sustained (2-year) IOP lowering in many eyes. A flexible administration schedule improved the safety profile of the implant over the fixed administration schedule.
Authors
- Margot L. Goodkin (ORCID: https://orcid.org/0000-0001-6392-3257)
- Kimmie Kim
- Harvey S. Uy (ORCID: https://orcid.org/0000-0002-2514-1278)
- Marina Bejanian
- Steven R. Sarkisian (ORCID: https://orcid.org/0000-0001-7633-2720)
- Miriam Kolko (ORCID: https://orcid.org/0000-0001-8697-0734)
- Andrew J. Tatham (ORCID: https://orcid.org/0000-0003-0372-3100)
- Kin Sheng Lim (ORCID: https://orcid.org/0000-0002-3897-1633)
- Michael Shiu
- Quoc Ho
- James D. Paauw
- Michael R. Robinson
- Anthony P. Wells
- Jenny Jiao
Institutions
- University of Copenhagen (DK)
- St Thomas' Hospital (GB)
- University of Lynchburg (US)
- Princess Alexandra Eye Pavilion (GB)
- Glostrup Hospital (DK)
- Copenhagen University Hospital (DK)
- New Zealand Association of Scientists (NZ)
- Allergan (Ireland) (IE)
- Centre for Eye Research Australia (AU)
- Dean McGee Eye Institute (US)
- Peregrine Eye and Laser Institute (PH)
Publication Details
- Journal
- American Journal of Ophthalmology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1016/j.ajo.2024.12.026
- Citations
- 9
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 15.36
Funders
- AbbVie